STAT3 inhibition resulted in increased anti-tumor activity and superior responses to immunotherapy and immunogenic chemotherapy in several pre-clinical studies and trials [163,164,165,166,167,168,169,170,171,172]. Here, STAT3 is linked to neoplasm.